系统性红斑狼疮患者使用胰高血糖素样肽-1受体激动剂的回顾性评估
在NYU狼疮队列中回顾性评估GLP1-RA在SLE患者中的结局,1211例中仅24例使用过GLP1-RA,18例纳入分析。随访6-10个月仅1例轻中度 flare,无患者累积新的SLE分类标准,中位BMI较基线下降3%(1-4个月,P=0.002)和13%(6-10个月,P=0.001)。
要点
- 18例SLE患者使用GLP1-RA,6-10个月仅1例轻中度flare,无新SLE标准累积。
- 中位BMI较基线下降3%(1-4个月,P=0.002)和13%(6-10个月,P=0.001)。
- 9例(50%)患者初始被保险公司拒绝覆盖GLP1-RA。
核心结论
- 作者认为,尽管样本量小,该描述性研究显示GLP1-RA未触发高于预期背景率的flare,并与BMI显著降低相关;未来探索GLP1-RA在SLE患者中潜在获益的研究是有必要的。
研究设计与样本
- 回顾性分析,纳入NYU狼疮队列中所有使用过GLP1-RA的患者,共24例,排除6例用药时长记录不足者,最终分析18例。
- 在基线(开始GLP1-RA前最近一次风湿科就诊)、开始后1-4个月和6-10个月评估患者特征。
主要发现
- 18例患者中位年龄50岁,17例(94%)为女性,9例(50%)为白人。
- 随访期间6-10个月出现1例轻中度flare,无患者累积新的SLE分类标准。
- 与基线相比,中位BMI在1-4个月降低3%(P=0.002),在6-10个月降低13%(P=0.001)。
- 9例(50%)患者初始被保险公司拒绝覆盖GLP1-RA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出该研究受小样本量限制。
- 原文结论提出未来探索GLP1-RA在SLE患者中潜在获益的研究是有必要的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications with demonstrated promise in improving cardiometabolic outcomes. Whether these drugs may be useful in mitigating the cardiac risk associated with SLE remains unknown, and a recent case of drug-induced lupus secondary to GLP1-RA use calls the safety of GLP1-RAs in SLE patients into question. Accordingly, this retrospective analysis was initiated to evaluate outcomes of GLP1-RAs in SLE. METHODS: All patients in the NYU Lupus Cohort who had used a GLP1-RA were eligible for inclusion. Patient characteristics were assessed at baseline (most recent rheumatology visit prior to starting GLP1-RA), 1-4 months and 6-10 months after GLP1-RA initiation. RESULTS: Of the 1211 patients in the cohort, only 24 had received a GLP1-RA. Six were excluded due to insufficient documentation regarding duration of medication use. Of the remaining 18 (median age 50), 17 (94%) were female and nine (50%) were White. There was one mild-to-moderate flare at 6-10 months, but no patients accumulated new SLE criteria during the follow-up period. Compared with baseline, median BMI was reduced by 3% at 1-4 months (P = 0.002) and 13% at 6-10 months (P = 0.001). Nine (50%) patients were initially denied insurance coverage for a GLP1-RA. CONCLUSION: While limited by a small sample size, this descriptive study showed that GLP1-RAs did not trigger flares above expected background rates and were associated with significantly decreased BMI. Future studies exploring the potential benefits of GLP1-RAs in patients with SLE are warranted.
引用
- Carlucci PM, Cohen B, Saxena A, et al. A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients. Rheumatology (Oxford). 2025. PMID: 39388251. doi:10.1093/rheumatology/keae547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。